Literature DB >> 17164048

Statistical issues in clinical trial design.

Kenneth R Hess1.   

Abstract

This paper reviews some of the more salient recent developments in statistical aspects of clinical trial design methodology and suggests that more emphasis be placed on rigorous assessments of the new methodologies to place them in the context of existing methods, demonstrate their claimed advantages, and fully disclose their remaining limitations.

Mesh:

Year:  2007        PMID: 17164048     DOI: 10.1007/bf02951426

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  15 in total

1.  Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.

Authors:  Peter F Thall; J Kyle Wathen; B Nebiyou Bekele; Richard E Champlin; Laurence H Baker; Robert S Benjamin
Journal:  Stat Med       Date:  2003-03-15       Impact factor: 2.373

2.  New designs for phase 2 clinical trials.

Authors:  Elihu H Estey; Peter F Thall
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

Review 3.  Competing designs for phase I clinical trials: a review.

Authors:  William F Rosenberger; Linda M Haines
Journal:  Stat Med       Date:  2002-09-30       Impact factor: 2.373

4.  FDA perspective on trials with interim efficacy evaluations.

Authors:  Robert Temple
Journal:  Stat Med       Date:  2006-10-15       Impact factor: 2.373

5.  Monitoring event times in early phase clinical trials: some practical issues.

Authors:  Peter F Thall; Leiko H Wooten; Nizar M Tannir
Journal:  Clin Trials       Date:  2005       Impact factor: 2.486

6.  Optimal two-stage designs for phase II clinical trials.

Authors:  R Simon
Journal:  Control Clin Trials       Date:  1989-03

7.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

Authors:  P F Thall; R M Simon; E H Estey
Journal:  Stat Med       Date:  1995-02-28       Impact factor: 2.373

8.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials.

Authors:  J Bryant; R Day
Journal:  Biometrics       Date:  1995-12       Impact factor: 2.571

9.  End points and United States Food and Drug Administration approval of oncology drugs.

Authors:  John R Johnson; Grant Williams; Richard Pazdur
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

Review 10.  Bayesian clinical trials.

Authors:  Donald A Berry
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.